Trusted by:
With 40,000 breast cancer deaths expected in the U.S. this year, cancer researchers continue with their mission to unlock the mysteries surrounding this disease. Implications for fine-tuned prognosis for breast cancer patients were unveiled at the annual AACR meeting in San Diego April 12 "鈥� 16.
Future treatment implications for melanoma and ovarian cancer were discussed at the annual AACR meeting in San Diego April 12 "鈥� 16. Use of the ALS drug Riluzole on melanoma and the effects of the mineral selenium on ovarian cancer when combined with the standard of care were among highlighted studies presented.
New research findings indicate the potential for more targeted treatment of ovarian cancer through the use of the mineral selenium in combination with the standard treatment for the disease.
New research to be published in JAMA shows a lack of survival benefit for older men with localized prostate cancer when administered a common hormone therapy. Authors say the treatment did not show any increase in the overall survival rate compared to conservative management.
Scientists at two New Jersey institutions have identified a long-sought gene responsible for metastasis in 30 to 40 percent of all breast cancer patients. The research, published in the January 6 edition of Cancer Cell, also describes how this gene is resistant to traditional chemotherapy treatments.
If you were being told that you were at genetic risk of developing breast cancer, would you want to find out over the phone? New research finds convenience plays a large role in the answer to that question.
A new robotic surgical technique developed for the removal of all or part of the prostate gland is showing what investigators call a "dramatic improvement"聺 in a male's sexual potency rate. The results were recently presented at the 26th World Congress Endourology meeting in Shanghai, China.
New research published in the Journal of Clinical Oncology shows a treatment combination used in breast and lung cancers to be effective against Hodgkin's disease in pre-teens and young adults, which make up to 10 to 15 of all U.S. cases. At focus are the drugs Gemcitabine and Vinorelbine.
A new study shows better survival outcomes for women who have ovarian and endometrial cancers at the same time than those who only have one tumor in the ovaries. The research from New Jersey's only Comprehensive Cancer Center is published in the April edition of Obstetrics and Gynecology.
Researchers from New Jersey's only NCI-designated Comprehensive Cancer Center are presenting findings on a combined treatment targeting breast cancer that is stimulated by the hormone estrogen. At focus is how the FDA-approved therapy fulvestrant can influence the effects of chemotherapy drugs on breast cancer cells.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right